Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026

Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique

View original at globenewswire.com
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères d'évaluation principaux et seco…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Two additional phase 3 studies, AQUA and ESTUARY, are expected to publish results in second half of 2026

    80% confidence

  • Amlitelimab's safety and efficacy profiles have not been evaluated by any regulatory authority; the product is currently in clinical development

    80% confidence

  • Global regulatory submissions are planned for second half of 2026

    80% confidence

  • The complete data observed to date reinforces confidence in amlitelimab's potential to offer both every-12-week dosing from treatment start and progressive efficacy through week 52

    80% confidence

  • These results validate the new mechanism of action of amlitelimab, which blocks OX40 ligand without destroying T cells, and its ability to normalize the immune system over time

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique — Source | Via News | ViaNews Market